At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see how well volrustomig works to treat people with inoperable head and neck squamous cell cancer (HNSCC). Inoperable means the cancer cannot be taken out with surgery. The people in this study have HNSCC that has not grown after chemotherapy and radiation given at the same time.
-
A mutation called G12C in a gene called KRAS may promote cancer growth. LY3537982 is an investigational drug that targets the mutated KRAS G12C protein. This targeting action may stop cancer cells from growing and dividing.
-
The usual care for people with squamous cell skin cancer is surgery, with or without radiation therapy. Sometimes the cancer comes back (recurs). For this reason, researchers are studying other treatments for squamous cell skin cancer.
-
When some cancers become advanced, particularly colorectal cancer, they may spread to the liver. Destroying the tissue with electromagnetic waves that produce extremely high temperatures, a procedure called "thermal ablation," is one way to treat these liver metastases.
-
Researchers are assessing ado-trastuzumab emtansine (T-DM1) to treat salivary gland cancer. The people in this study have cancer that is operable (can be removed with surgery) and makes a protein called HER2. T-DM1 targets cancer cells that make HER2. In this study, it will be combined with radiation therapy and chemotherapy after the tumor has been removed by surgery.
- A Phase II Study of Trastuzumab Deruxtecan in People with HER2-Positive Solid Tumors
Full Title A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)
Purpose
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
Trastuzumab deruxtecan is an antibody drug conjugate (ADC). ADCs have two parts: the antibody targets cancer cells and the other part (a chemotherapy drug attached to the antibody) kills cancer cells. Trastuzumab, the antibody part, binds to HER2 on cancer cells. Deruxtecan is the cell-killing part. When trastuzumab sticks to HER2, deruxtecan is released and kills the cancer cell from within.
Trastuzumab deruxtecan is approved to treat metastatic breast cancer; its use in this study is investigational. It is given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have inoperable or metastatic HER2-positive biliary tract, bladder, cervical, endometrial, ovarian, or pancreatic cancer or a rare tumor.
- At least 4 weeks must pass since completion of prior therapy and receipt of trastuzumab deruxtecan.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Vicky Makker at 646-888-4224.
Protocol
21-078Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04482309ClinicalTrials.gov
-
The purpose of this study is to see how treatment for retinoblastoma in one eye affects quality of life in survivors of this cancer who had chemotherapy (injected into the eye) or surgery to remove the eye. Researchers will ask participants about their physical and emotional health and ability to perform daily activities. They want to determine if there are any differences between these treatments with respect to their effect on quality of life. It is hoped that this information will help doctors provide better care for children with retinoblastoma in the future and better follow-up care for survivors of this cancer.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
- A Phase 2 Study of Tebentafusp in People With Advanced Clear Cell Sarcoma
Full Title SARC045: A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients with Advanced Clear Cell Sarcoma
Purpose
Researchers want to see how well tebentafusp works in people with clear cell sarcoma that has spread. This cancer grows deeply into soft tissues of the arms and legs. The people in this study have clear cell sarcoma that is inoperable (cannot be surgically removed) or has spread.
Tebentafusp is a type of drug called a bispecific protein, which means it binds to two different proteins. It binds to one protein on cancer cells and another on immune cells called T cells. Tebentafusp may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have inoperable or metastatic clear cell sarcoma.
- Be positive for HLA-A*02:01. HLA is an antigen on the surface of your cells.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Sandra P. D’Angelo’s office at 646-888-4159.
Protocol
25-249Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06942442ClinicalTrials.gov
-
Researchers want to learn if BGB-11417 given alone or with dexamethasone and carfilzomib may help people with multiple myeloma. The people in this study have multiple myeloma that keeps growing after standard treatment. BGB-11417 blocks a protein called Bcl-2 that helps multiple myeloma cells to live and grow.